COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

被引：0
|
作者：
Xiao, D. [1 ]
Zhu, S. [1 ]
Sun, W. [2 ]
Xuan, J. [3 ]
机构：
[1] Shanghai Centennial Sci Co Ltd, Shanghai, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.831
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIH31
引用
收藏
页码：S187 / S188
页数：2
相关论文
共 50 条
  • [31] Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
    Gu, Shuyan
    Zeng, Yuhang
    Yu, Demin
    Hu, Xiaoqian
    Dong, Hengjin
    PLOS ONE, 2016, 11 (11):
  • [32] Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
    Nguyen, Trang T. H.
    Mital, Shweta
    PHARMACOECONOMICS, 2025, 43 (03) : 351 - 361
  • [33] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [34] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Guan, Haijing
    Wang, Chunping
    Zhao, Zhigang
    Han, Sheng
    ADVANCES IN THERAPY, 2022, 39 (07) : 3334 - 3346
  • [35] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Haijing Guan
    Chunping Wang
    Zhigang Zhao
    Sheng Han
    Advances in Therapy, 2022, 39 : 3334 - 3346
  • [36] Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States.
    Zhong, Yichen
    Lai, Yizhen
    Li, Haojie
    Batteson, Rachael
    Meng, Yang
    Frenkl, Tara L.
    Godwin, James Luke
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Second-Line Therapy for Patients With Hepatocellular Carcinoma
    Frenette, Catherine T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
  • [38] COST-EFFECTIVENESS OF AFATINIB AND ERLOTINIB AS SECOND-LINE TREATMENTS FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG IN CHINA
    Zhu, J.
    Ye, M.
    Fu, J.
    Wu, B.
    Chu, Y.
    Zhao, Y.
    Zhang, Y.
    Kuo, D.
    Su, B.
    VALUE IN HEALTH, 2017, 20 (09) : A442 - A442
  • [39] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [40] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE PHARMACOLOGICAL TREATMENTS OF ACROMEGALY IN SPAIN
    Peral, C.
    Cordido, F.
    Gimeno, V
    Sanchez-Cenizo, L.
    Mir, N.
    Parrondo, J.
    VALUE IN HEALTH, 2017, 20 (09) : A557 - A558
12345